The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.
Yvonne H. Yeung
No relevant relationships to disclose
Fiona J.M. Chionh
No relevant relationships to disclose
Timothy Jay Price
Consultant or Advisory Role - Novartis (U)
Andrew Mark Scott
No relevant relationships to disclose
Hoanh Tran
No relevant relationships to disclose
Guangying Fang
No relevant relationships to disclose
Effie Skrinos
No relevant relationships to disclose
Carmel Murone
No relevant relationships to disclose
John M Mariadason
No relevant relationships to disclose
Niall C. Tebbutt
No relevant relationships to disclose